Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2

AIDS Research and Human Retroviruses

Volumn 24, Issue 10, 2008, Pages 1275-1280

  Pozniak, Anton ^a   Opravil, Milos ^b   Beatty, George ^c   Hill, Andrew ^d   De Béthune, Marie Pierre ^e   Lefebvre, Eric ^f  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e TIBOTEC BVBA   (Belgium)

^f Tibotec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; LOPINAVIR; RITONAVIR; SAQUINAVIR;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 53849147582     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0275     Document Type: Article

References (16)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC): Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, October 10, 2006.
2. Ledergerber B, Egger M, Opravil M, et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353:863-868.
3. Tibotec Inc: Prezista (darunavir) prescribing information, October 2006. Available at http://www.prezista.com/prescribing_information.html. Accessed March 14, 2007.
4. PREZISTA: Summary of product characteristics (EMEA). Tibotec Pharmaceuticals Ltd., Yardley, PA.
5. De Meyer S, Azijn H, Surleraux D, et al.: TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005;49:2314-2321.
6. de Bethune MP and Hertogs K: Screening and selecting for optimized antiretroviral drugs: Rising to the challenge of drug resistance. Curr Med Res Opin 2006;22:2603-2612.
7. Katlama C, Esposito R, Gatell JM, et al.: Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007;21:395-402.
8. Haubrich RH, Berger D, Chiliade P, et al.: Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007;21:F11-F18.
9. D'Aquila RT, Schapiro JM, Brun-Vezinet F, et al.: Drug resistance mutations in HIV-1. Top HIV Med 2003;11:92-96.
10. De Meyer S, Vangeneugden T, Lefebvre E, et al.: Phenotypic and genotypic determinants of TMC114 (darunavir) resistance: POWER 1, 2 and 3 pooled analysis. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 12-16 2006. Abstract P196.
11. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 2005;13:51-57.
12. Clotet B, Bellos N, Molina JM, et al.: Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-1178.
13. De Meyer S, Vangeneugden T, Van Baelen B, et al.: Resistance profile of darunavir: Combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008;24(3):379-388.
14. Pozniak A, Saag M, Bellos N, et al.: Efficacy of TMC114/r in treatment-experienced HIV patients: Factors influencing outcome in the pooled 24-week analysis of POWER 1, 2 and 3. 12th Annual Conference of the British HIV Association (BHIVA), Brighton, UK, March 29-April 1 2006. Abstract P3.
15. Molina JM, Cohen C, Katlama C, et al.: TMC114 in treatment-experienced HIV patients in POWER 3: 24-week efficacy and safety analysis. J Acquir Immune Defic Syndr 2007;46(1):24-31.
16. Rockstroh J, Clumeck N, Spinosa Guzman S, De Paepe E, and Lefebvre E: Darunavir (TMC114)/r has tolerability and efficacy benefits for treatment-experienced patients compared with control PIs: Overview of the POWER trials. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 12-16, 2006. Abstract P28.